Goldman Sachs
May 13, 2026
Shionogi Earnings Review Sales Solid But Profits Miss Expectations
Single Stock ReportEquitiesHealth Care
Shionogi reported FY3/26 results that missed profit expectations due to high investment costs, resulting in a maintained Neutral rating and ¥3,300 target price.
Key Takeaways
- 1.FY3/26 operating profits of ¥166.7 bn missed GSe of ¥186.4 bn due to higher SG&A costs and impairment losses on pipeline products.
- 2.FY3/27 operating profit guidance of ¥220 bn is below previous estimates, primarily due to increased R&D and edaravone inventory costs.
- 3.The Neutral rating is maintained as the current share price offers little valuation appeal, with future growth dependent on HIV pipeline and JT synergies.
Table of Contents
- Results overview and GSe revisions
- Price Target Risks and Methodology - Shionogi & Co.
- Investment Thesis - Shionogi & Co.
- Disclosure Appendix
Document Preview
Access the Full Report
Get unlimited access to institutional research reports with a 14-day free trial.
Authors
Akinori Ueda, Ph.D.Tomo Taniguchi
Securities
4507.T2914.T
Themes
R&D Investment for GrowthPatent Cliff Management
Regions
Asia PacificJapan
